{'fraction_non_alphanumeric': 0.02442002442002442, 'fraction_numerical': 0.003663003663003663, 'mean_word_length': 5.890756302521009, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Multimodality magnetic resonance imaging of prostate cancer.

The purpose of this article is to review both routine T2-weighted and new MRI techniques in the imaging of prostate cancer (PCa) for focal therapy. T2-weighted imaging, knowledge of MRI prostate zonal anatomy, cancer morphology, and intraprostatic tumor spread remain essential for clinical PCa imaging; however, new techniques, such as dynamic contrast-enhanced MRI, diffusion-weighted imaging, and magnetic resonance spectroscopic imaging yield significant improvements in identification and volume estimation. Potential advantages of 3 Tesla MRI are adequate imaging without an endorectal coil. Future studies should work toward helping define standard, reproducible approaches to multimodality MRI and image reporting for research and clinical practice.